ANCA-associated vasculitic neuropathy during treatment with ipilimumab

Rheumatology (Oxford). 2020 Jan 1;59(1):251-252. doi: 10.1093/rheumatology/kez235.

¹ Department of Autoimmune Diseases, Vasculitis Research Unit.
² Department of Dermatology, Melanoma Unit.
³ Department of Internal Medicine, Muscle Research Unit, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, Spain.
⁴ Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Spain.
⁵ Department of Neurology, EMG Unit, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, Spain.

No abstract available

Publication types

Adult
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / chemically induced*
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / diagnosis
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / immunology
Antibodies, Antineutrophil Cytoplasmic / immunology*
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use
Biopsy
Buttocks
Female
Humans
Ipilimumab / adverse effects*
Ipilimumab / therapeutic use
Melanoma / drug therapy*
Skin Neoplasms / drug therapy*
Tomography, X-Ray Computed